ArticleCureus2026
Urgent Chemotherapy for Aggressive Metastatic Neuroendocrine Cancer With Impending Hepatic Failure: A Case Report.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Neuroendocrine carcinoma is a rare, biologically diverse malignancy that frequently presents with metastatic disease, which can carry a poor prognosis. Its symptomatology is often nonspecific, resulting in delayed diagnosis with substantial tumor burden. Platinum-based chemotherapy remains the cornerstone of treatment, although outcomes remain poor and novel therapeutic strategies are needed. We report a case of newly diagnosed metastatic neuroendocrine cancer in a patient presenting with vague constitutional and gastrointestinal symptoms, ultimately complicated by impending hepatic failure from extensive liver involvement. Initial evaluation raised greater concern for lymphoma or thyroid malignancy, given the pattern of lymphadenopathy and imaging findings. However, tissue biopsy ultimately revealed metastatic neuroendocrine carcinoma. This case underscores the aggressive nature of the poorly differentiated neuroendocrine carcinoma subtype, the importance of early recognition, and the challenges of managing patients with rapidly progressive disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.